These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 3263689

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics.
    Sanders CC, Sanders WE.
    J Infect Dis; 1986 Nov; 154(5):792-800. PubMed ID: 3490520
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the E test and microdilution for detection of beta-lactam-resistant mutants that are stably derepressed for type I beta-lactamase.
    Knapp CC, Washington JA.
    J Clin Microbiol; 1992 Jan; 30(1):214-5. PubMed ID: 1734054
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Induction potency of various beta-lactam derivatives in gram-negative rods.
    Cullmann W, Dick W.
    Chemotherapy; 1989 Jan; 35(1):43-53. PubMed ID: 2785904
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Beta-lactam antibiotics and beta-lactamases: two sides of a continuing story.
    Richmond MH.
    Rev Infect Dis; 1979 Jan; 1(1):30-8. PubMed ID: 400938
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. beta-Lactamases of gram-negative bacteria: new challenges for new drugs.
    Sanders CC.
    Clin Infect Dis; 1992 May; 14(5):1089-99. PubMed ID: 1600011
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bacterial resistance mechanisms to beta-lactam antibiotics: assessment of management strategies.
    Dudley M.
    Pharmacotherapy; 1995 May; 15(1 Pt 2):9S-14S. PubMed ID: 7753692
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
    Jones RN, Sader HS, Fritsche TR.
    Diagn Microbiol Infect Dis; 2005 May; 52(1):71-4. PubMed ID: 15878447
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
    Yoshizumi A, Ishii Y, Aoki K, Testa R, Nichols WW, Tateda K.
    J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.